https://de.marketscreener.com/kurs/aktie/ASTELLAS-PHARMA-INC-6491262/news/Astellas-Pharma-startet-klinische-Phase-3-Studien-mit-Fezolinetant-zur-Behandlung-von-VMS-in-Verbind-46092920/?utm_source=telegram&utm_medium=social&utm_campaign=share